The following is a summary of “Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and ...
The first recipient of a gene-edited pig kidney died from cardiac causes 52 days after xenotransplantation. The world's first ...
Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.
Pharmaceutical Technology on MSN11h
Genentech eyes lupus market for Gazyva with positive Phase III data readoutGenentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...
DAVENPORT & Co LLC reduced its position in shares of argenx SE (NASDAQ:ARGX – Free Report) by 5.1% during the fourth quarter, ...
We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...
Technologies announced that it has entered into definitive agreements with a single healthcare focused institutional investor for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback